TCGA-D6-6515-01A-21R-1873-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.092009132
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.740
- INTERFERON_GAMMA_RESPONSE+0.650
- ALLOGRAFT_REJECTION+0.570
- IL6_JAK_STAT3_SIGNALING+0.470
- COMPLEMENT+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.390
- INFLAMMATORY_RESPONSE+0.350
- ANGIOGENESIS+0.340
- NOTCH_SIGNALING+0.340
- COAGULATION+0.300
Top 10 suppressed
- MYC_TARGETS_V2-0.470
- CHOLESTEROL_HOMEOSTASIS-0.420
- OXIDATIVE_PHOSPHORYLATION-0.380
- MYC_TARGETS_V1-0.340
- HYPOXIA-0.330
- GLYCOLYSIS-0.320
- DNA_REPAIR-0.250
- PANCREAS_BETA_CELLS-0.220
- UNFOLDED_PROTEIN_RESPONSE-0.210
- SPERMATOGENESIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R187 | — | — | 0.858 |
| 2 | TCGA-CR-7392-01A-11R-2016-07 | — | — | 0.858 |
| 3 | TCGA-CR-7382-01A-11R-2132-07 | — | — | 0.850 |
| 4 | TCGA-CR-7377-01A-11R-2016-07 | — | — | 0.846 |
| 5 | cf9ea065-c101-48e2-a1ea-54eb01658eef | — | — | 0.841 |
| 6 | TCGA-CN-4733-01A-02R-1873-07 | — | — | 0.839 |
| 7 | DRR168577 | — | — | 0.834 |
| 8 | TCGA-CR-7376-01A-11R-2132-07 | — | — | 0.834 |
| 9 | TCGA-CV-6943-01A-11R-1915-07 | — | — | 0.834 |
| 10 | 653522fe-3289-4e1f-9373-c81f923893a3 | — | — | 0.831 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.740 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.650 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.570 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.470 | Inavolisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.390 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.350 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.270 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| MYOGENESIS | 0.220 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.160 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |